[go: up one dir, main page]

NO971900D0 - Mixtures and treatment of multiple sclerosis - Google Patents

Mixtures and treatment of multiple sclerosis

Info

Publication number
NO971900D0
NO971900D0 NO971900A NO971900A NO971900D0 NO 971900 D0 NO971900 D0 NO 971900D0 NO 971900 A NO971900 A NO 971900A NO 971900 A NO971900 A NO 971900A NO 971900 D0 NO971900 D0 NO 971900D0
Authority
NO
Norway
Prior art keywords
mixtures
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
NO971900A
Other languages
Norwegian (no)
Other versions
NO971900L (en
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of NO971900D0 publication Critical patent/NO971900D0/en
Publication of NO971900L publication Critical patent/NO971900L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO971900A 1994-10-25 1997-04-24 Mixtures and treatment of multiple sclerosis NO971900L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (2)

Publication Number Publication Date
NO971900D0 true NO971900D0 (en) 1997-04-24
NO971900L NO971900L (en) 1997-06-25

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971900A NO971900L (en) 1994-10-25 1997-04-24 Mixtures and treatment of multiple sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (en)
JP (1) JPH10504039A (en)
AU (1) AU4278296A (en)
BR (1) BR9509438A (en)
CA (1) CA2203629A1 (en)
CZ (1) CZ122697A3 (en)
FI (1) FI971750A7 (en)
HU (1) HUT77047A (en)
IL (1) IL115766A0 (en)
IS (1) IS4466A (en)
NO (1) NO971900L (en)
PL (1) PL324091A1 (en)
SI (1) SI9520118A (en)
SK (1) SK51297A3 (en)
WO (1) WO1996012737A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
CA2247009C (en) 1996-03-21 2009-08-04 Imperial College Of Science, Technology And Medicine Cryptic peptides and method for their identification
CA2263730A1 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (en) * 1997-09-11 1997-09-11 Astra Ab Peptides
CA2330826A1 (en) * 1998-05-05 1999-11-11 Corixa Corporation Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
EP1080110A2 (en) * 1998-05-19 2001-03-07 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
BR0308923A (en) 2002-03-27 2005-01-04 Aegera Therapeutics Inc Antisense iap nucleobase oligomers and uses of these
DE10230381A1 (en) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
EP2413958A4 (en) 2009-03-31 2014-04-02 Univ East Carolina CYTOKINES AND NEUROANTIGENES FOR THE TREATMENT OF IMMUNE DISEASES
CN102781465A (en) 2009-10-12 2012-11-14 生命生物实验室有限公司 Composition for treatment of multiple sclerosis
RU2448685C2 (en) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Liposomes containing oligopeptides - fragments of myelin basic protein, pharmaceutical composition and method of treating multiple sclerosis
EP2688904B1 (en) * 2011-03-21 2017-12-27 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
EP3094341B1 (en) 2014-01-13 2019-10-02 Berg LLC Enolase 1 (eno1) compositions and uses thereof
ES2940607T3 (en) 2015-12-03 2023-05-09 Juno Therapeutics Inc Modified Chimeric Receptors and Related Compositions and Methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359783B2 (en) * 1987-06-24 2002-04-17 Autoimmune, Inc. Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
DK0506785T3 (en) * 1989-12-20 2000-07-24 Autoimmune Inc Improved treatment of autoimmune diseases by aerosol administration of autoantigens
HUT61896A (en) * 1990-03-02 1993-03-29 Autoimmune Inc Process for producing orally administrable pharmaceutical compositions comprising autoantigenes, suitable for improving down-control of autoimmune diseases
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
WO1993009810A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
JP3712260B2 (en) * 1992-02-28 2005-11-02 オートイミューン インク Bystander suppression of autoimmune diseases
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
ATE170874T1 (en) * 1992-04-09 1998-09-15 Autoimmune Inc SUPPRESSION OF T-CELL PROLIFERATION USING PEPTIDE FRAGMENTS OF MYELIN BASIC PROTEIN
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
NZ273813A (en) * 1993-09-03 1998-05-27 Immulogic Pharma Corp Myelin oligodendrocyte glycoprotein autoantigen
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
CA2172512A1 (en) * 1993-09-22 1995-03-30 Lawrence Steinman Interaction of t-cell receptors and antigen in autoimmune disease
CA2187345A1 (en) * 1994-04-08 1995-10-19 Howard L. Weiner Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
CA2185353A1 (en) * 1994-04-08 1995-10-19 David A. Hafler Treatment of autoimmune disease using oral tolerization and/or type i interferon
SI9520059A (en) * 1994-05-10 1997-08-31 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis.
DK0764273T3 (en) * 1994-06-09 1999-06-23 Tno Alpha B crystallin for use in the diagnosis and therapy of autoimmune diseases, especially multiple sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
ATE213499T1 (en) * 1994-11-18 2002-03-15 Neurocrine Biosciences Inc PEPTIDE ANALOGUES OF HUMAN BASIC MYELIN PROTEIN WITH SUBSTITUTION AT POSITION 91 FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Also Published As

Publication number Publication date
WO1996012737A3 (en) 1996-10-10
FI971750A7 (en) 1997-06-24
AU4278296A (en) 1996-05-15
IS4466A (en) 1997-04-17
JPH10504039A (en) 1998-04-14
SK51297A3 (en) 1998-03-04
PL324091A1 (en) 1998-05-11
CZ122697A3 (en) 1997-09-17
BR9509438A (en) 1997-12-23
EP0787147A1 (en) 1997-08-06
SI9520118A (en) 1998-08-31
CA2203629A1 (en) 1996-05-02
FI971750A0 (en) 1997-04-24
HUT77047A (en) 1998-03-02
NO971900L (en) 1997-06-25
IL115766A0 (en) 1996-01-19
WO1996012737A2 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
NO971900D0 (en) Mixtures and treatment of multiple sclerosis
NO972125D0 (en) Hemorrhoids mixtures and methods of use
NO933240L (en) Arrangement and preparation of toothbrush
DE69415068D1 (en) Micromotor and manufacturing process of the same
DE69406116D1 (en) CLEANING COMPOSITION AND METHOD OF USE
NO971015D0 (en) Compounds and Methods for the Treatment of Cancer
FI964874A0 (en) Treatment of vegetables
NO940277D0 (en) Triglycerides and mixtures thereof
NO934547D0 (en) Oral treatment of Helicobacter-in-infection
DE69331967D1 (en) CONVENTIONAL AND RELATED INTRODUCTION DEVICE
NO953991D0 (en) Piezotype ultrasomic and electrosurgical handpiece
DE69607321D1 (en) CLEANING PROCEDURE AND COMPOSITION
NO965563D0 (en) Treatment and prophylaxis of osteoporosis
FI972245A7 (en) Meso-monoiodosubstituted tetramacrocyclic compounds and methods of preparation and use thereof
FI965204A0 (en) Medical use of bromelain
FI951060A7 (en) Formulations and treatment methods
DE69333528D1 (en) D-N-CARBAMOYLAMINOSAUREAMIDOHYDROLASE AND HYDANTOINASE
NO961790L (en) Combination of appliance base and insert part
NO961226L (en) Compounds for the prevention and treatment of viral-induced tumors
NO982463D0 (en) Use of a combination of pentoxyphylline and type I interferons for the treatment of multiple sclerosis
NO952568D0 (en) Treatment of cellulose material and compositions for use therefor
FI963263A0 (en) Medical use of bromelain
NO931399D0 (en) USE OF NATURSTEIN
NO962503D0 (en) Use of penoxyphylline in the treatment of multiple sclerosis
DE69503929D1 (en) Treatment of gas mixtures